Clinical Data ECO 2026: tirzepatide shows potential for T1D treatment Pharmaceutical TechnologyDuring ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in treating type 1 diabetes (T1D).Metabolic & GLP-1Read full story pharminent May 15, 2026 Pharmaceutical Technology During ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in treating type 1 diabetes (T1D). Metabolic & GLP-1 Read full story Post navigation Previous: Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidateNext: Biopharma industry endorses Pazdur for FDA commissioner role Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026